Back

Systolic plood pressure response to ASi BI 690517 with and without empagliflozin in CKD

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Hypertension management: drugs Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Peter Rossing

Steno Diabetes Center, Copenhagen, Herlev (Denmark)

7 More presentations in this session

Presentation thumbnail
Adherence to anti-hypertensive therapy with perindopril-based single-pill versus free-pill combinations: a 10-year real-world analysis in Italy
Associate Professor A. Vintila (Bucharest, RO)
Abstract Slides Video
Presentation thumbnail
The expanding role of semaglutide in cardiovascular disease and its the effect on blood pressure
Doctor C. Kennedy (Dublin, IE)
Abstract Slides Video
Presentation thumbnail
Real-world analysis exploring the association between anti-hypertensive therapy with perindopril-based single-pill combinations (SPC) and cardiovascular outcomes and all-cause mortality in Italy
Doctor S. Masi (Pisa, IT) Associate Professor J. Wolf (Gdansk, PL)
Abstract Slides Video
Presentation thumbnail
Injectable angiotensinogen inhibition therapy for hypertension: a systematic review and meta-analysis
Doctor A. Yadav (New Delhi, IN)
Abstract Slides Video
Presentation thumbnail
A higher adherence to perindopril-based anti-hypertensive therapy is associated with a reduced risk of cardiovascular outcomes and all-cause mortality in real clinical practice in Italy
Doctor S. Masi (Pisa, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Hypertension management: drugs

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Panel discussion - SOGALDI-PEF
thumbnail
Congress Presentation
Improving outcomes for the heart and kidney: the role of mineralocorticoid receptor antagonists (MRAs)
thumbnail
Congress Presentation
Acute over-additive natriuretic effects by a combination of finerenone and SGLT2 inhibition in rats with an activated renin-angiotensin-aldosterone system: a mechanistic basis for clinical outcomes?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources